Effects of once-daily versus twice-daily darunavir/ritonavir on lipid parameters at week 48 in treatment-experienced, HIV-1-infected patients with no darunavir resistance-associated mutations (RAMs) in the ODIN study

被引：0
|
作者：
Arribas, J. [1 ]
Arathoon, E. [2 ]
Gonsalez, C. R. [3 ]
Latiff, G. H. [4 ]
Van De Casteele, T. [5 ]
De Doncker, P. [5 ]
De La Rosa, G. [6 ]
Spinosa-Guzman, S. [5 ]
机构：
[1] Hosp Univ La Paz, IdiPAZ, Madrid, Spain
[2] Clin Familiar Luis Angel Garcia, Guatemala City, Guatemala
[3] Univ Sao Paulo, Hosp Clin, Fac Med, Pinheiros, Brazil
[4] Maxwell Ctr, Durban, South Africa
[5] Tibotec BVBA, Beerse, Belgium
[6] Tibotec Therapeut, Titusville, NJ USA
来源：
ANTIVIRAL THERAPY | 2010年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：A59 / A60
页数：2
相关论文
共 50 条
  • [21] Simplification from twice-daily to once-daily darunavir/ritonavir in a randomized trial among HIV-infected persons with HIV-1 RNA suppression on antiretroviral therapy
    Huhn, Gregory D.
    Sigman, Andrew
    Livak, Britt
    ANTIVIRAL THERAPY, 2015, 20 (08) : 849 - 854
  • [22] Once- versus twice-daily lopinavir/ritonavir tablets in virologically suppressed, HIV-infected, treatment-experienced children: comparative pharmacokinetics and virological outcome after switching to once-daily lopinavir/ritonavir
    Chokephaibulkit, Kulkanya
    Nuntarukchaikul, Maneeratn
    Phongsamart, Wanatpreeya
    Wittawatmongkol, Orasri
    Lapphra, Keswadee
    Vanprapar, Nirun
    Cressey, Tim R.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2012, 67 (12) : 2927 - 2931
  • [23] Week 48 results of a Phase IV trial of etravirine with antiretrovirals other than darunavir/ritonavir in HIV-1-infected treatment-experienced adults
    Arathoon, Eduardo
    Bhorat, Asad
    Silaghi, Rodica
    Crauwels, Herta
    Lavreys, Ludo
    Tambuyzer, Lotke
    Vanveggel, Simon
    Opsomer, Magda
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2014, 17 : 177 - 178
  • [24] Meta-analysis of once-daily and twice-daily lopinavir/ritonavir combined with NRTIs in HIV-1-infected, a ntiretroviral-naive patients
    van Wyk, Jean
    Qaqish, Roula
    Hollar, Kimberly
    White, Kelly
    D'Amico, Ronald
    Norton, Michael
    Chiu, Yi-Lin
    King, Martin
    FUTURE VIROLOGY, 2012, 7 (01) : 103 - 113
  • [25] Pharmacokinetics and Virological Efficacy after Switch to Once-Daily Lopinavir-Ritonavir in Treatment-Experienced HIV-1-Infected Children
    Foissac, Frantz
    Urien, Saik
    Hirt, Deborah
    Frange, Pierre
    Chaix, Marie-Laure
    Treluyer, Jean-Marc
    Blanche, Stephane
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (09) : 4320 - 4325
  • [26] Once-daily versus twice-daily Lopinavir/Ritonavir in antiretroviral-naive HIV-positive patients: A 48-week randomized clinical trial
    Eron, JJ
    Feinberg, J
    Kessler, HA
    Horowitz, HW
    Witt, MD
    Carpio, FF
    Wheeler, DA
    Ruane, P
    Mildvan, D
    Yangco, BG
    Bertz, R
    Bernstein, B
    King, MS
    Sun, E
    JOURNAL OF INFECTIOUS DISEASES, 2004, 189 (02): : 265 - 272
  • [27] The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetic profile of once-daily ritonavir-boosted darunavir in HIV-1-infected subjects
    Garvey, L.
    Latch, N.
    Erlwein, O.
    Mohammed, P.
    Mackie, N.
    Walsh, J.
    Scullard, G.
    McClure, M.
    Dickinson, L.
    Back, D.
    Winston, A.
    HIV MEDICINE, 2010, 11 : 23 - 24
  • [28] Model-Based Once-Daily Darunavir/Ritonavir Dosing Recommendations in Pediatric HIV-1-Infected Patients Aged >= 3 to <12 Years
    Brochot, A.
    Kakuda, T. N.
    Van De Casteele, T.
    Opsomer, M.
    Tomaka, F. L.
    Vermeulen, A.
    Vis, P.
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2015, 4 (07): : 406 - 414
  • [29] A Randomized Phase 3 Study Comparing Once-Daily Elvitegravir With Twice-Daily Raltegravir in Treatment-Experienced Subjects With HIV-1 infection: 96-Week Results
    Elion, Richard
    Molina, Jean-Michel
    Lopez, Jose Ramn Arribas
    Cooper, David
    Maggiolo, Franco
    Wilkins, Edmund
    Conway, Brian
    Liu, Ya-Pei
    Margot, Nicolas
    Rhee, Martin
    Chuck, Steven L.
    Szwarcberg, Javier
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2013, 63 (04) : 494 - 497
  • [30] NON-INFERIORITY OF ONCE-DAILY COBICISTAT-BOOSTED DARUNAVIR VERSUS RITONAVIR-BOOSTED DARUNAVIR IN HIV-1-INFECTED ADULT PATIENTS: AN ADJUSTED COMPARATIVE ANALYSIS OF POOLED PHASE 3 DATA
    Van Sanden, S.
    Thilakarathne, P.
    Opsomer, M.
    Mrus, J.
    Vanveggel, S.
    Lathouwers, E.
    Adriaenssen, I
    VALUE IN HEALTH, 2014, 17 (07) : A664 - A664
12345